A new diabetes drug that sits in the same class as Byetta has been found to be effective in cutting blood sugar levels and lowering weight, following a year long study involving people with type 2 diabetes .
The drug, liraglutide, is based on a hormone called GLP-1 that stimulates insulin secretion. Related drugs called DPP-4 inhibitors are also concerned with the hormone, although in a slightly different way. DPP-4 inhibitors include Galvus and Januvia .
Byetta has been in the news lately for having a rare side effect called pancreatitis. It is not yet clear whether liraglutide will cause a similar response amongst an extreme minority of patients.
The study, conducted by the Baylor College of Medicine, compared liraglutide to Amaryl, another diabetic drug .

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…

Coronavirus: UK instructed to stay at home this weekend

Health Secretary Matt Hancock has said that staying at home this weekend…

Conversation about doctors’ appointments occurring virtually rumbles on

More than half of GP appointments are still being delivered remotely in…